Dong-A St (170900) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Dong-A St stock KRW 10,616, price KRW 34,000, that is 68.8% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Dong-A St
170900 · KOFar too expensive (fair value 69% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 18, 2026.
How to read this chart
60‑month range 32,000 KRW – 83,714 KRW · fair‑value band 10,616 KRW – 22,764 KRW · the 34,000 KRW price screens above the 10,616 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 18, 2026.
Every Wednesday you see whether Dong-A St is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
Show moreShow less
It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature, small for gestational age, turner syndrome; Leucostim Inj. for neutropenia in patients receiving myelosuppressive chemotherapy; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab/ Stillen 2X tab. to treat gastritis; Suganon tab./Sugamet XR tab. and Sugadapa tab./Sugatree XR tab for type 2 diabetes mellitus; DA-3880 PFS to treat renal anemia and darbepoetin-alfa; and Zydena tab. for erectile dysfunction treatment.
The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery.
Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
Stock analysis
Dong-A St (170900) currently trades at 34,000 KRW, while our model-based Fair Value estimate is 10,616 KRW, 69% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 91/100, which puts the data coverage at medium.
Scenario range: 10,616 KRW (bear) to 22,764 KRW (bull), the price of 34,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Dong-A St reported revenue of 809B KRW in FY2025 versus 593B KRW in FY2021, a compound +8.1%/yr. Reported net income was −28.6B KRW in FY2025.
Key figures
Market cap 327B KRW (≈ $246M) Micro · P/E ratio 37.6 · P/S ratio 0.38 · EPS (TTM) 901.60 KRW · Dividend yield 2.1% · Net margin 1.0% · Return on equity 0.9% · Return on assets (EBIT) 0.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (medium confidence).
What moves the price
The share trades about 37% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −69%, 170900 screens richer than that median.
Fair Value models
All 2 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
170900 screens overvalued: fair value 69% below the price. Compare with Merck KGaA →
Compare Dong-A St with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Quality Score by industry
- Return on equity by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $85.57 | $113.53 | +33% | vs 170900 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.88 | ¥52.43 | +12% | vs 170900 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,900 | ₹1,983 | +4% | vs 170900 |
| Haleon plc HLN | $9.08 | $8.47 | −7% | vs 170900 |
| Merck KGaA MRK | €148.40 | €108.83 | −27% | vs 170900 |
| Galderma Group GALD | CHF 184.70 | CHF 112.46 | −39% | vs 170900 |
| Takeda Pharmaceutical Company TAK | $21.27 | $11.23 | −47% | vs 170900 |
| Sandoz Group SDZ | CHF 81.24 | CHF 41.06 | −49% | vs 170900 |
| Teva Pharmaceutical Industries Limited TEVA | $42.23 | $20.74 | −51% | vs 170900 |
| Divi's Laboratories Limited DIVISLAB | ₹11,178 | ₹1,567 | −86% | vs 170900 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Dong-A St (170900) overvalued or undervalued?
What is the fair value of 170900?
What is the quality score of 170900?
What is the price target for Dong-A St (170900)?
What is the Dong-A St stock forecast for 2026?
What is the revenue of Dong-A St (170900)?
Does Dong-A St pay a dividend?
How much is the dividend of Dong-A St (170900) and when is the ex-dividend date?
What is the intrinsic value of Dong-A St (170900)?
Is Dong-A St stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 170900?
How much is Dong-A St worth?
What do the bullish and bearish scenarios say about 170900?
What is the P/E ratio of 170900?
How solid is the balance sheet of Dong-A St (170900)?
How far is 170900 from its 52-week high?
Which stocks are comparable to Dong-A St?
Is Dong-A St stock attractive at the current price?
How is the fair value of 170900 calculated?
Is it still worth investing in stocks now?
What is the share price of Dong-A St (170900)?
What should I pay attention to with Dong-A St right now?
Key figures of Dong-A St
How large is the market capitalisation of Dong-A St (170900)?
What is the P/S ratio of Dong-A St (170900)?
What are the earnings per share of Dong-A St (170900)?
What is the dividend yield of Dong-A St (170900)?
What is the net margin of Dong-A St (170900)?
What is the return on equity of Dong-A St (170900)?
What is the EBIT return on assets of Dong-A St (170900)?
What is the operating margin of Dong-A St (170900)?
How fast is revenue growing at Dong-A St (170900)?
How fast are earnings growing at Dong-A St (170900)?
How much free cash flow does Dong-A St (170900) generate?
How much net debt does Dong-A St (170900) carry?
Watch Dong-A St in the live analysis
One click puts Dong-A St on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.